Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia

od Phelps, Mitch A., Lin, Thomas S., Johnson, Amy J., Hurh, Eunju, Rozewski, Darlene M., Farley, Katherine L., Wu, Di, Blum, Kristie A., Fischer, Beth, Mitchell, Sarah M., Moran, Mollie E., Brooker-McEldowney, Michelle, Heerema, Nyla A., Jarjoura, David, Schaaf, Larry J., Byrd, John C., Grever, Michael R., Dalton, James T.
Wydane 2009

Flavopiridol administered using a pharmacologically derived schedule is associated with marked clinical efficacy in refractory, genetically high-risk chronic lymphocytic leukemia

od Byrd, John C., Lin, Thomas S., Dalton, James T., Wu, Di, Phelps, Mitch A., Fischer, Beth, Moran, Mollie, Blum, Kristie A., Rovin, Brad, Brooker-McEldowney, Michelle, Broering, Sarah, Schaaf, Larry J., Johnson, Amy J., Lucas, David M., Heerema, Nyla A., Lozanski, Gerard, Young, Donn C., Suarez, Jose-Ramon, Colevas, A. Dimitrios, Grever, Michael R.
Wydane 2007